APD-514 eyedrops for treatment of EKC
| Reference number | |
| Coordinator | Adenovir SA Development AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | July 2015 - February 2016 |
| Status | Completed |
Important results from the project
Pharmaceutical development with different formulations for an optimal eye drop formulation. These formulations have been tested in a serie of different in vitro tests performed at Department of Virology Umeå University. Good binding capacity have been confirmed. The objective to have a formulation that can be transferred to an industrial development company has been reached. Process for a national paten application in key countries has started in US, EU, Japan, China, etc.
Expected long term effects
Pharmaceutical development with different formulations for an optimal eye drop formulation, which has a confirmed good efficacy in a serie of different in vitro tests. The objective to have a formulation that can be transferred to an industrial development company has been reached. Process for a national paten application in key countries has started in US, EU, Japan, China, etc.
Approach and implementation
Together with MediGelium at KI, a serie of different formulations with well-known excipients together with APD-514. The objective has been to find an optimal formulation with different buffer systems and anti-oxidants that enables a stable and optimal formulation with high binding capacity of adenovirus in vitro performed at Dept of Virology Umeå University.